COMMUNIQUÉS West-GlobeNewswire

Dova Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
05/03/2019
DURHAM, N.C., March 05, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the Cowen [...]
Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences
05/03/2019
AUSTIN, Texas, March 05, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new [...]
Dragon Jade Announces Appointments of New Independent Directors and Formation of Nominating and Compensation Committees
05/03/2019
HONG KONG, March 05, 2019 (GLOBE NEWSWIRE) -- Dragon Jade International Limited (“Dragon Jade” or “the Company”) (OTCQX: DGJI), a provider of premier products and services, today announced the appointments of Mr. David [...]
Retrophin to Present at Upcoming Investor Conferences
05/03/2019
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March: Cowen [...]
The Cooper Companies Announces First Quarter 2019 Results
05/03/2019
PLEASANTON, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE: COO) today announced financial results for the fiscal first quarter ended January 31, 2019. Revenue increased 6% year-over-year to [...]
Alpha Pro Tech, Ltd. Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2018
05/03/2019
Revenue for the fourth quarter of 2018 was $11.0 million, an increase of 10% compared to $9.9 million for the fourth quarter of 2017. Revenue for the year ended December 31, 2018 increased 5.9% to $46.6 million, [...]
Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
05/03/2019
BURLINGAME, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted [...]
DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update
05/03/2019
Montrouge, France, March 5, 2019 DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical- [...]
DBV Technologies annonce ses résultats financiers pour l’exercice 2018 et fait un point sur ses activités
05/03/2019
Montrouge, France, 5 mars (22h10 CET) 2019 DBV Technologies annonce ses résultats financiers pour l’exercice 2018 et fait un point sur ses activités DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT [...]
IRIDEX Announces 2018 Fourth Quarter and Full Year Financial Results
05/03/2019
MOUNTAIN VIEW, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018. Fourth Quarter Highlights Cyclo G6 ® [...]
Prothena to Participate in Upcoming March Healthcare Conferences
05/03/2019
DUBLIN, Ireland, March 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate [...]
Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference
05/03/2019
HOUSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming investor conference: [...]
Tabula Rasa HealthCare Announces Acquisition of PrescribeWellness Expanding its Medication Risk Mitigation Offering
05/03/2019
MOORESTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced that it has acquired [...]
CytomX to Present at Upcoming Healthcare Conferences
05/03/2019
SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody [...]
Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results
05/03/2019
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway – – Data from three ongoing Phase 2 trials of tipifarnib anticipated this year – – Third drug candidate menin-MLL inhibitor KO-539 poised to [...]
Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock
05/03/2019
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market [...]
Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
05/03/2019
STAMFORD, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the [...]
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/03/2019
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates ( [...]
Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
05/03/2019
- Phase 1 Trial of Sleeping Beauty -TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in [...]

Pages